A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)
2001-0001
Phase 1 other active
Quick answer
A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours) for Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours
- Phase
- Phase 1
- Modality
- other
- Status
- active